13.04.2014 Views

CP13/6 - CRD IV for Investment Firms - Financial Conduct Authority

CP13/6 - CRD IV for Investment Firms - Financial Conduct Authority

CP13/6 - CRD IV for Investment Firms - Financial Conduct Authority

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>CP13</strong>/6<br />

<strong>CRD</strong> <strong>IV</strong> <strong>for</strong> <strong>Investment</strong> <strong>Firms</strong><br />

7. It is important to note that the major economic benefits arising from implementation of <strong>CRD</strong><br />

<strong>IV</strong> come from increased financial stability and reduced macro-prudential risk. Such benefits<br />

generally arise from regulation of systemically important institutions. Most FCA regulated<br />

firms will not fall under the systemically important category. When considering the overall<br />

cost-benefit impact of <strong>CRD</strong> <strong>IV</strong>, there<strong>for</strong>e, the analysis contained in this document should be<br />

considered alongside the CBA produced by the PRA.<br />

8. The implementation of <strong>CRD</strong> <strong>IV</strong> will have a direct impact on the regulatory costs experienced<br />

by investment firms. The large majority of such costs arise as a result of new Regulation (in<br />

particular COREP/FINREP) and the transposition of the Directive. Such policy changes are not<br />

subject to FCA discretion but we need to consider the cost arising from rule changes that result<br />

from Directive transposition. In addition, although we would not usually assess the impact of a<br />

Regulation as part of a CBA, this CBA presents estimates of costs arising from the Regulation as<br />

they represent the bulk of the costs to be incurred by investment firms. It is important that any<br />

incremental impact arising from UK optional policy changes should be placed in such context.<br />

9. We have not presented detailed estimates <strong>for</strong> the costs associated with individual articles since:<br />

• in many cases it is not possible to separate the incremental impact of each element of the<br />

overall package; and<br />

• it is difficult to differentiate the impacts from provisions in Regulations from those of<br />

changed requirements arising from transposition of Directives.<br />

10. Incremental costs and benefits arising from “optional” exercise of national discretions and<br />

derogations are likely to be small relative to those due to the Regulation and transposition<br />

of the Directive. As described in Chapter 1, where discretions and derogations have been<br />

available, the general approach has been to ensure costs <strong>for</strong> incumbent investment firms are<br />

minimised. Where appropriate and feasible, the estimates of impacts have been presented in<br />

the relevant CP chapter.<br />

11. This CBA estimates the overall impact of the Directive and the Regulation against a baseline in<br />

which the Directive is not transposed and the Regulation is not introduced.<br />

The market affected<br />

12. The implementation of <strong>CRD</strong> <strong>IV</strong> will impact FCA-regulated markets including (activity types):<br />

• venture capital/private equity;<br />

• investment management;<br />

• brokerage firms;<br />

• inter-broker dealer;<br />

• other non-capital-intensive business (custody, corporate finance, advice).<br />

13. <strong>CRD</strong> <strong>IV</strong> implementation will alter the rules and guidance that apply to around 2,400 investment<br />

firms regulated by the FCA. These investment firms are diverse in nature, as shown in Table 14,<br />

below.<br />

62 July 2013<br />

<strong>Financial</strong> <strong>Conduct</strong> <strong>Authority</strong>

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!